Novel prevention strategies for bacterial infections in cirrhosis

References

• Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33(1):41–48.
   PubMedGoogle Scholar
• Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55(5):1551–1561.
   PubMed Web of Science ®Google Scholar
• Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1256.e5.
   PubMed Web of Science ®Google Scholar
• Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis: in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol. 2001;96(4):1232–1236.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care–associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8(11):979–985.e1.
   PubMed Web of Science ®Google Scholar
• Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Supplement 1):S1–S12.
   Google Scholar
• Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18(3):353–358.
   PubMed Web of Science ®Google Scholar
• Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2016;77:14–25.
   PubMed Web of Science ®Google Scholar
• Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis. J Hepatol. 2005;42(2):195–201.
   PubMed Web of Science ®Google Scholar
• Falguera M, Trujillano J, Caro S, et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis. 2009;49(3):409–416.
   PubMed Web of Science ®Google Scholar
• Fernández J, Tandon P, Mensa J, et al. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology. 2015. [Epub ahead of print].
   Google Scholar
• Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology. 2004;39(3):746–753.
   PubMed Web of Science ®Google Scholar
• Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818–824.
   PubMed Web of Science ®Google Scholar
• Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29(6):1655–1661.
   PubMed Web of Science ®Google Scholar
• Tandon P, DeLisle A, Topal JE, et al. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a us liver center. Clin Gastroenterol Hepatol. 2012;10(11):1291–1298.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–1324.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2009;105(1):106–113.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis: Update 2012. AASLD Practice Guidelines. 2013;57(4):1651–1653.
   Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.
   PubMed Web of Science ®Google Scholar
• De Franchis R. Expanding consensus in portal hypertension: report of the baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752.
   PubMed Web of Science ®Google Scholar
• Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis. 1988;157(5):1032–1038.
   PubMed Web of Science ®Google Scholar
• Marteau P, Pochart P, Doré J, et al. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol. 2001;67(10):4939–4942.
   PubMed Web of Science ®Google Scholar
• Quigley EMM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(2, Supplement):S78–S90.
   Google Scholar
• Casafont Morencos F, De Las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996;41(3):552–556.
   PubMed Web of Science ®Google Scholar
• Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26(6):1372–1378.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–2967.
   PubMed Web of Science ®Google Scholar
• Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29(12):1273–1281.
   PubMed Web of Science ®Google Scholar
• Koh IH, Guatelli R, Montero EF, et al. Where is the site of bacterial translocation - small or large bowel? Transplant Proc. 1996;28(5):2661.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bartoli R, March F, et al. Translocated intenstinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol. 1998;28(2):307–313.
   PubMed Web of Science ®Google Scholar
• Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209.
   PubMed Web of Science ®Google Scholar
• Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26(1):17–25.
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. New England J Med. 2010;362(12):1071–1081.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE. 2013;8(4):e60042.
   PubMed Web of Science ®Google Scholar
• Dupont HL. Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother. 2011;12:293–302.
   PubMed Web of Science ®Google Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390–1397.e2.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450–455.
   PubMed Web of Science ®Google Scholar
• Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46(8):709–715.
   PubMed Web of Science ®Google Scholar
• Lutz P, Parcina M, Bekeredjian-Ding I, et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One. 2014;9(4):e93909.
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74(1):123–127.
   PubMed Web of Science ®Google Scholar
• Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol. 2002;37(4):456–462.
   PubMed Web of Science ®Google Scholar
• Adawi D, Ahrne S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol. 2001;70(3):213–220.
   PubMed Web of Science ®Google Scholar
• Sánchez E, Neito JC, Boullosa A, et al. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int. 2015;35(3):735–745.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Fernandez J, Navasa M, et al. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol. 2002;36(4):501–506.
   PubMed Web of Science ®Google Scholar
• Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology. 2000;31(4):858–863.
   PubMed Web of Science ®Google Scholar
• Zhang SC, Wang W, Ren WY, et al. Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis. World J Gastroenterol. 2003;9(3):534–538.
   PubMed Web of Science ®Google Scholar
• Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31(1):43–38.
   PubMed Web of Science ®Google Scholar
• Ding JW, Andersson R, Soltesz V, et al. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res. 1993;25(1):11–19.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Zuniga V, Bartoli R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37(3):551–557.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Farre R, Verbinnen, Covens K, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015;185(2):409–419.
   PubMed Web of Science ®Google Scholar
• Ubeda M, Borrero MJ, Lario M, et al. O153 The Farnesoid X Receptor Agonist, Obeticholic Acid, improves intestinal antibacterial defense and reduces gut bacterial translocation and hepatic fibrogenesis in CCl4-cirrhotic rats with ascites. J Hepatol. 2014;60(1, Supplement): S63.
   Google Scholar
• Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–3925.
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am J Transplant. 2005;5(1):125–130.
   PubMed Web of Science ®Google Scholar
• Lata J, Novotny I, Pribramska V, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastro Hepatol. 2007;19(12):1111–1113.
   PubMed Web of Science ®Google Scholar
• Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39(5):1441–1449.
   PubMed Web of Science ®Google Scholar
• Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur J Gastro Hepatol. 2012;24(7):831–839.
   PubMed Web of Science ®Google Scholar
• Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96(4):1251–1255.
   PubMed Web of Science ®Google Scholar
• Sandhu BS, Gupta R, Sharma J, et al. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol. 2005;20(4):599–605.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–921.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Cholongitas E, Burra P, et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189–1193.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–369.
   PubMed Web of Science ®Google Scholar
• Garg V, Garg H, Khan A, et al. Granulocyte colony–stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–512.e1.
   PubMed Web of Science ®Google Scholar
• Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;19(7):1104–1110.
   PubMed Web of Science ®Google Scholar
• Kedarisetty CK, Anand L, Bhardwaj A, et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology. 2015;148(7):1362–1370.e7.
   PubMed Web of Science ®Google Scholar
• Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611–618.
   PubMed Web of Science ®Google Scholar
• Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol. 2015;66(4):483–491.
   PubMed Web of Science ®Google Scholar
• Smits LP, Bouter KEC, De Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–953.
   PubMed Web of Science ®Google Scholar
• Freedman A, Eppes S. 1805 use of stool transplant to clear fecal colonization with carbapenem-resistant enterobacteraciae (CRE): proof of concept. Open Forum Infect Dis. 2014;1(suppl 1): S65.
   Google Scholar
• Kao D, Roach B, Park H, et al. Fecal microbiota transplantation (FMT) in the management of hepatic encephalopathy (HE). Hepatology. 2016;63(1):339–340.
   PubMed Web of Science ®Google Scholar
• Chang CS, Chen G, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28(5):1187–1190.
   PubMed Web of Science ®Google Scholar
• Code CF. The interdigestive housekeeper of gastrointestinal tract. Propect Biol Med. 1987;22:549–555.
   Google Scholar
• Sarker SA, Gyr K. Non-immunological defence mechanisms of the gut. Gut. 1992;33(7):987–993.
   PubMed Web of Science ®Google Scholar
• Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993;17(5):828–832.
   PubMed Web of Science ®Google Scholar
• Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98(6):1362–1370.
   PubMed Web of Science ®Google Scholar
• Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42(4):738–742.
   PubMed Web of Science ®Google Scholar
• Chander Roland B, Garcia-Tsao G, Ciarleglio MM, et al. Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhosis and healthy controls. J Clin Gastroenterol. 2013;47(10):888–893.
   PubMed Web of Science ®Google Scholar
• Madrid AM, Brahm J, Buckel E, et al. Orthotopic liver transplantation improves small bowel motility disorders in cirrhotic patients. Am J Gastroenterol. 1997;92(6):1044–1045.
   PubMed Web of Science ®Google Scholar
• Freestone PPE, Haigh RD, Williams PH, et al. Stimulation of bacterial growth by heat stable norepinephrine-induced autoinducers. FEMS Microbiol Lett. 1999;172(1):53–60.
   PubMed Web of Science ®Google Scholar
• Lyte M, Ernst S. Catecholamine induced growth of gram negative bacteria. Life Sci. 1992;50(3):203–212.
   PubMed Web of Science ®Google Scholar
• Abraldes J, Tandon P. The use of beta-blockers in advanced cirrhosis—where do we stand? Curr Hepatol Rep. 2015;14(1):46–52.
   Google Scholar
• Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422–433.
   PubMed Web of Science ®Google Scholar
• Aranow JS, Fink MP. Determinants of intestinal barrier failure in critical illness. Br J Anaesth. 1996;77(1):71–81.
   PubMed Web of Science ®Google Scholar
• Spaeth G, Gottwald T, Specian RD, et al. Secretory immunoglobulin A, intestinal mucin, and mucosal permeability in nutritionally induced bacterial translocation in rats. Ann Surg. 1994;220(6):798–808.
   PubMed Web of Science ®Google Scholar
• Levi AC, Borghi F, Petrino R, et al. Modifications of the trophism of intestinal mucosa after intestinal and bilio-pancreatic diversion in the rat. Ital J Gastroenterol. 1991;23:202–207.
   PubMedGoogle Scholar
• Bertok L. Bile acids and endotoxins: physico-chemical defense of the body. Orvosi Hetil. 1999;140(1):3–8.
   PubMedGoogle Scholar
• Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003;50(53):1482–1486.
   PubMed Web of Science ®Google Scholar
• Assimakopoulos SF, Tsamandas AG, Tsiaoussis GI, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest. 2012;42(4):439–446.
   PubMed Web of Science ®Google Scholar
• Genescà J, Marti R, Rojo F, et al. Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut. 2003;52(7):1054–1059.
   PubMed Web of Science ®Google Scholar
• Saitoh O, Sugi K, Kojima K, et al. Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol. 1999;5(5):391–396.
   PubMed Web of Science ®Google Scholar
• Teltschik Z, Wiest R, Beisner J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised paneth cell antimicrobial host defense. Hepatology. 2012;55(4):1154–1163.
   PubMed Web of Science ®Google Scholar
• Sung JY, Shaffer E, Costerton JW. Antibacterial activity of bile salts against common pathogens. Effects of hydrophobicity of the molecule and the presence of phospholipids. Dig Dis Sci. 1993;38:2104–2112.
   PubMed Web of Science ®Google Scholar
• Floch MH, Gershengoren W, Elliott S, et al. Bile acid inhibition of the intestinal microflora - a function for simple bile acids. Gastroenterology. 1971;61:228–233.
   PubMed Web of Science ®Google Scholar
• Slocum MM, Sittig KM, Specian RD, et al. Absence of intestinal bile promotes bacterial translocation. Am Surg. 1992;58(5):305–310.
   PubMed Web of Science ®Google Scholar
• Lutz P, Berger C, Langhans B, et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis. 2014;46(11):1047–1050.
   PubMedGoogle Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol. 2009;51(3):426–429.
   PubMed Web of Science ®Google Scholar
• O’Brien AJ, Fullerton JN, Massey KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med. 2014;20(5):518–523.
   PubMed Web of Science ®Google Scholar
• Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol. 2011;55(3):574–581.
   PubMed Web of Science ®Google Scholar
• Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(9):727–738.
   PubMed Web of Science ®Google Scholar
• Gaia S, Olivero A, Smedile A, et al. Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. Hepatol Int. 2013;7(4):1075–1083.
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651–1658.
   PubMed Web of Science ®Google Scholar
• Mohanty A, Tate J, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis. Gastroenterology. 2016;150(2):430–440.
   PubMed Web of Science ®Google Scholar